Jazz Pharmaceuticals plc

144.30+0.7100+0.49%Vol 524.30K1Y Perf -13.17%
Jan 14th, 2022 16:00 DELAYED
BID142.50 ASK150.00
Open143.95 Previous Close143.59
Pre-Market- After-Market145.00
 - -  0.70 0.49%
Target Price
202.31 
Analyst Rating
Strong Buy 1.21
Potential %
40.20 
Finscreener Ranking
★★★★     52.12
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★     47.73
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★+     43.91
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
37.36 
Earnings Rating
Strong Buy
Market Cap8.87B 
Earnings Date
22nd Feb 2022
Alpha-0.01 Standard Deviation0.09
Beta0.95 

Today's Price Range

143.72145.88

52W Range

117.64189.00

5 Year PE Ratio Range

9.5030.60

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
7.34%
1 Month
18.54%
3 Months
2.56%
6 Months
-19.14%
1 Year
-13.17%
3 Years
12.73%
5 Years
23.02%
10 Years
208.99%

TickerPriceChg.Chg.%
JAZZ144.300.71000.49
AAPL173.070.88000.51
GOOG2 795.7313.11000.47
MSFT310.205.40001.77
XOM71.871.24001.76
WFC58.062.06003.68
JNJ167.84-0.9200-0.55
FB331.905.42001.66
GE103.160.70000.68
JPM157.89-10.3400-6.15
Financial StrengthValueIndustryS&P 500US Markets
1.60
3.60
0.62
1.62
1.40
Leverage Ratio 2.70
ProfitabilityValueIndustryS&P 500US Markets
87.60
10.30
26.30
19.90
-13.39
RevenueValueIndustryS&P 500US Markets
2.20B
35.75
15.76
9.56
Earnings HistoryEstimateReportedSurprise %
Q03 20212.603.6440.00
Q02 20212.923.2912.67
Q01 20213.093.4210.68
Q04 20203.583.56-0.56
Q03 20203.533.869.35
Q02 20202.963.2610.14
Q01 20200.21-0.05-123.81
Q04 20193.614.0411.91
Earnings Per EndEstimateRevision %Trend
12/2021 QR2.871.06Positive
12/2021 FY13.12-10.14Negative
3/2022 QR3.07-74.35Negative
12/2022 FY14.24--
Next Report Date22nd Feb 2022
Estimated EPS Next Report2.87
Estimates Count5
EPS Growth Next 5 Years %13.80
Volume Overview
Volume524.30K
Shares Outstanding61.47M
Shares Float53.59M
Trades Count11.85K
Dollar Volume81.28M
Avg. Volume818.39K
Avg. Weekly Volume1.11M
Avg. Monthly Volume666.44K
Avg. Quarterly Volume603.70K

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) stock closed at 144.3 per share at the end of the most recent trading day (a 0.49% change compared to the prior day closing price) with a volume of 527.31K shares and market capitalization of 8.87B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 1940 people. Jazz Pharmaceuticals plc CEO is Bruce C. Cozadd.

The one-year performance of Jazz Pharmaceuticals plc stock is -13.17%, while year-to-date (YTD) performance is 13.27%. JAZZ stock has a five-year performance of 23.02%. Its 52-week range is between 117.64 and 189, which gives JAZZ stock a 52-week price range ratio of 37.36%

Jazz Pharmaceuticals plc currently has a PE ratio of -53.10, a price-to-book (PB) ratio of 2.10, a price-to-sale (PS) ratio of 4.10, a price to cashflow ratio of 10.00, a PEG ratio of 2.32, a ROA of -1.72%, a ROC of -0.02% and a ROE of -4.42%. The company’s profit margin is -13.39%, its EBITDA margin is 26.30%, and its revenue ttm is $2.20 Billion , which makes it $35.75 revenue per share.

Of the last four earnings reports from Jazz Pharmaceuticals plc, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $2.87 for the next earnings report. Jazz Pharmaceuticals plc’s next earnings report date is 22nd Feb 2022.

The consensus rating of Wall Street analysts for Jazz Pharmaceuticals plc is Strong Buy (1.21), with a target price of $202.31, which is +40.20% compared to the current price. The earnings rating for Jazz Pharmaceuticals plc stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Jazz Pharmaceuticals plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Jazz Pharmaceuticals plc has a Buy technical analysis rating based on Technical Indicators (ADX : 9.09, ATR14 : 4.38, CCI20 : 117.22, Chaikin Money Flow : 0.12, MACD : 4.61, Money Flow Index : 73.31, ROC : 9.71, RSI : 66.37, STOCH (14,3) : 70.58, STOCH RSI : 0.34, UO : 55.62, Williams %R : -29.42), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Jazz Pharmaceuticals plc in the last 12-months were: Bruce C. Cozadd (Option Excercise at a value of $1 941 197), Bruce C. Cozadd (Sold 44 293 shares of value $6 431 027 ), Catherine A. Sohn (Sold 1 306 shares of value $193 236 ), Elmar Schnee (Sold 1 632 shares of value $251 328 ), Heather Ann McSharry (Sold 1 414 shares of value $209 215 ), Jennifer Cook (Sold 417 shares of value $50 582 ), Kenneth W. O'Keefe (Sold 1 306 shares of value $193 236 ), Kim Sablich (Sold 2 748 shares of value $371 000 ), Norbert G. Riedel (Sold 1 306 shares of value $193 236 ), Patricia Carr (Sold 4 257 shares of value $685 609 ), Paul L. Berns (Sold 1 450 shares of value $223 300 ), Peter P. Gray (Sold 1 414 shares of value $209 215 ), Rick E. Winningham (Sold 1 306 shares of value $193 236 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
12 (85.71 %)
13 (86.67 %)
13 (81.25 %)
Moderate Buy
1 (7.14 %)
1 (6.67 %)
2 (12.50 %)
Hold
1 (7.14 %)
1 (6.67 %)
1 (6.25 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.21
Strong Buy
1.20
Strong Buy
1.25

Jazz Pharmaceuticals plc

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and indications in neuroscience and hematology-oncology. Jazz's product portfolio includes its lead drug, Xyrem, for narcolepsy, Sunosi for improving wakefulness in patients with excessive daytime sleepiness, Defitelio for severe veno-occlusive disease after stem cell transplant, Vyxeos for acute myeloid leukemia, and Zepzelca for small cell lung cancer.

CEO: Bruce C. Cozadd

Telephone: +353 16347800

Address: Waterloo Road, Dublin D04 E5W7, , IE

Number of employees: 1 940

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

71%29%

Bearish Bullish

51%49%

Bearish Bullish

55%45%

TipRanks News for JAZZ

Tue, 16 Nov 2021 11:15 GMT Analysts Top Healthcare Picks: Jazz Pharmaceuticals (JAZZ), Altimmune (ALT)

- TipRanks. All rights reserved.

Wed, 10 Nov 2021 14:07 GMT Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Bayer (OtherBAYRY) and Applied Genetic Technologies (AGTC)

- TipRanks. All rights reserved.

Tue, 19 Oct 2021 11:37 GMT Analysts Are Bullish on Top Healthcare Stocks: Jazz Pharmaceuticals (JAZZ), BiomX (PHGE)

- TipRanks. All rights reserved.

Thu, 14 Oct 2021 10:15 GMT Analysts Offer Insights on Healthcare Companies: Alimera (ALIM), Jazz Pharmaceuticals (JAZZ) and Anavex Life Sciences (AVXL)

- TipRanks. All rights reserved.

Mon, 16 Aug 2021 10:25 GMT Analysts Top Healthcare Picks: Jazz Pharmaceuticals (JAZZ), Biohaven Pharmaceutical Holding Co (BHVN)

- TipRanks. All rights reserved.

Thu, 12 Aug 2021 08:39 GMT What Investors Can Learn from Jazz Pharmaceuticals Newly Added Risk Factors

- TipRanks. All rights reserved.

Tue, 10 Aug 2021 09:41 GMT Jazz Pharmaceuticals (JAZZ) Receives a Buy from RBC Capital

- TipRanks. All rights reserved.

Thu, 05 Aug 2021 07:23 GMT Jazz Pharmaceuticals (JAZZ) Received its Third Buy in a Row

- TipRanks. All rights reserved.

News

Stocktwits